Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVA) in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE) are presented. The recommendations are aimed at all healthcare personnel caring for women in the menopausal transition or postmenopausal phase, and are also intended to raise awareness of VVA. Recent data clearly indicate VVA is a highly prevalent condition among postmenopausal women, and that the vast majority of women with VVA are not adequately treated. In reality, diagnosis of VVA is simple and largely clinical. Many types of treatments are available for VVA, ranging from preventive education measures to local non-hormonal therapies, local agents that modulate hormonal receptors and systemic as well as laser therapy and radiofrequency. Regardless of the therapeutic approach adopted, greater communication between the physician and the woman with VVA should be actively encouraged. This is also in light of the difficulty of talking about the VVA and related disorders. Greater communication also encourages adequate therapy and thus minimizes the impact of VVA on the quality of life of the woman and her partner.

Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE)

Biglia N;Ambroggio S;Grassi G;
2019-01-01

Abstract

Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVA) in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE) are presented. The recommendations are aimed at all healthcare personnel caring for women in the menopausal transition or postmenopausal phase, and are also intended to raise awareness of VVA. Recent data clearly indicate VVA is a highly prevalent condition among postmenopausal women, and that the vast majority of women with VVA are not adequately treated. In reality, diagnosis of VVA is simple and largely clinical. Many types of treatments are available for VVA, ranging from preventive education measures to local non-hormonal therapies, local agents that modulate hormonal receptors and systemic as well as laser therapy and radiofrequency. Regardless of the therapeutic approach adopted, greater communication between the physician and the woman with VVA should be actively encouraged. This is also in light of the difficulty of talking about the VVA and related disorders. Greater communication also encourages adequate therapy and thus minimizes the impact of VVA on the quality of life of the woman and her partner.
2019
71
5
345
352
https://www.minervamedica.it/en/journals/minerva-ginecologica/article.php?cod=R09Y2019N05A0345
Atrophy; Postmenopause; Diagnosis; Guideline; Quality of life; Atrophy; Female; Humans; Physician-Patient Relations; Quality of Life; Vaginal Diseases; Vulvar Diseases; Perimenopause; Postmenopause
Cagnacci A.; Gallo M.; Gambacciani M.; Lello S.; Volpe A, Lanzone A, Di Carlo C, De Leo V, Biglia N, Caruso S, Cicinelli E, Farris M, Gambera A, Guasc...espandi
File in questo prodotto:
File Dimensione Formato  
Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy_SIGITE.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 847.04 kB
Formato Adobe PDF
847.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
MinervaGinecol_2019_Oct.pdf

Accesso aperto

Descrizione: post print
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 194.77 kB
Formato Adobe PDF
194.77 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1735088
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact